We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Reply: Clinical efficacy of lenvatinib for the treatment of radioiodine‐refractory thyroid carcinoma: A systematic review and meta‐analysis of clinical trials.
- Authors
Su, Jingyang; Fu, Yue; Wang, Menglei; Lin, Shengyou
- Abstract
Defining radioiodine-refractory differentiated thyroid cancer: efficacy and safety of lenvatinib by radioiodine-refractory criteria in the SELECT trial. What's more, Nair's paper, published in 2015, was a summary of the FDA's approval of lenvatinib for radioiodine-resistant thyroid cancer treatment, and the data here were identical to those in the SELECT study. Keywords: lenvatinib; meta-analysis; radioiodine-refractory thyroid carcinoma; systematic review EN lenvatinib meta-analysis radioiodine-refractory thyroid carcinoma systematic review 275 276 2 01/03/23 20230201 NES 230201 We read with great interest the paper by Yan et al., sharing the perspective that lenvatinib is beneficial for the treatment of radioiodine-refractory thyroid cancer in terms of the extension of progression-free survival (PFS) and overall survival (OS).[1] We greatly appreciated the authors' contributions in studying the treatment of thyroid cancer refractory to radioactive iodine, however, it seems to be some critical problems when the authors drew to this conclusion.
- Subjects
THYROID cancer; CLINICAL trials; TREATMENT effectiveness; IODINE isotopes; JAPANESE people; CONSOLIDATED financial statements
- Publication
Clinical Endocrinology, 2023, Vol 98, Issue 2, p275
- ISSN
0300-0664
- Publication type
Article
- DOI
10.1111/cen.14718